Who is sponsoring NCT05023057?

NCT05023057 is sponsored by Inha University Hospital.

What drugs are being tested in NCT05023057?

Interventions in NCT05023057: Multidomain intervention.

What condition does NCT05023057 study?

NCT05023057 studies Mild Cognitive Impairment.

Is NCT05023057 still recruiting?

NCT05023057 is currently completed. Last updated 4 December 2024.

Last reviewed 2024-12-04 · How we verify

NCT05023057: SUPERBRAIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multidomain Interventions Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment

Completed NA Last updated 4 December 2024

What this trial tests

NA trial testing Multidomain intervention in Mild Cognitive Impairment in 300 participants. Completed in 22 March 2023.

Timeline

23 September 2021

Primary endpoint
22 March 2023

22 March 2023

Quick facts

Lead sponsor	Inha University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	300
Start date	23 September 2021
Primary completion	22 March 2023
Estimated completion	22 March 2023
Sites	17 locations across South Korea

Drugs / interventions tested

Multidomain intervention

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Inha University Hospital

Who can join

Adults 60 to 85, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be done to investigate the effectiveness of a 24-week multidomain intervention program consisting of cognitive training, exercise, nutrition management, vascular disease risk factor management, social activity, and motivational enhancement on the cognitive function compared to the control group in mild cognitive impairment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face-to-face and video communication platforms in mild cognitive impairment (SUPERBRAIN-MEET): A randomized controlled trial.
Moon SY, Park YK, Jeong JH, Hong CH, et al · · 2025 · cited 18× · PMID 39840755 · DOI 10.1002/alz.14517
SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN health through Multidomain interventions via facE-to-facE and video communication plaTforms in mild cognitive impairment (SUPERBRAIN-MEET): Protocol for a Multicenter Randomized Controlled Trial.
Cho SH, Kang HJ, Park YK, Moon SY, et al · · 2024 · cited 6× · PMID 38362052 · DOI 10.12779/dnd.2024.23.1.30
Developing digital biomarker for predicting cognitive response to multi-domain intervention.
Park JH, Kim HS, Choi SH, Jeong JH, et al · · 2026 · PMID 41617781 · DOI 10.1038/s41598-026-37123-8
Polygenicity and APOE ε4 shape response to intervention in mild cognitive impairment.
Hwang J, Moon SY, Lee H, Lee J, et al · · 2025 · PMID 41388319 · DOI 10.1186/s13195-025-01907-3

Verify or expand the search:

Other trials of Multidomain intervention

Trials testing the same drug.

NCT07524478 — A Randomized Controlled Trial of a Multi-domain Smartphone Intervention Incorporating Generative AI for Healthy Older Ad · NA · recruiting
NCT06666829 — Multicenter Study That Offers New Solutions for Paediatric Rehabilitation by Proposing a Rehabilitation Plan Based on Ea · NA · recruiting
NCT05301868 — Multidomain Intervention Via a None-face-to-face Platform in Mild Cognitive Impairment · NA · unknown
NCT03095820 — Multidomain Intervention for Older Adults With Major Depressive Disorder · NA · completed
NCT03056768 — Taiwan Health Promotion Intervention Study for Elders · NA · completed

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Inha University Hospital trials

Trials by the same sponsor.

NCT07306520 — Effects of the Health Promotion Program on Health Literacy, Physical and Mental Health Status, and Quality of Life · NA · active not recruiting
NCT05659420 — High Intensity Interval Training in Chronic Heart Failure · NA · unknown
NCT06573268 — Da-vinci sp Versus xi Thyroid Surgery · completed
NCT05873023 — Chewing Gum and Cognitive Function · NA · unknown
NCT06963372 — Assessment of Health Effects of Air Purifier Interventions on Chronic Kidney Disease Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05023057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inha University Hospital
Last refreshed: 4 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05023057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing